EARLY PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES WITH ABT-494 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE OR TUMOR NECROSIS FACTOR INHIBITORS: POST-HOC ANALYSIS OF PHASE 2 RANDOMIZED CONTROLLED TRIALS

被引：0
|
作者：
Strand, V. [1 ]
Tundia, N. [2 ]
Song, I. H. [2 ]
Meerwein, S. [2 ]
Lin, J. [2 ]
Chen, N. [2 ]
Friedman, A. [2 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] AbbVie Inc, N Chicago, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.1143
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0217
引用
收藏
页码：855 / 855
页数：1
相关论文
共 50 条
  • [1] PATIENT-REPORTED OUTCOMES FROM A PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS
    Smolen, J. S.
    Kremer, J.
    Gaich, C.
    DeLozier, A. M.
    Schlichting, D.
    Xie, L.
    Genovese, M. C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 785 - 786
  • [2] Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
    Ana-Maria Orbai
    Philip J. Mease
    Philip S. Helliwell
    Oliver FitzGerald
    Dona L. Fleishaker
    Rajiv Mundayat
    Pamela Young
    [J]. BMC Rheumatology, 6
  • [3] Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
    Orbai, Ana-Maria
    Mease, Philip J.
    Helliwell, Philip S.
    FitzGerald, Oliver
    Fleishaker, Dona L.
    Mundayat, Rajiv
    Young, Pamela
    [J]. BMC RHEUMATOLOGY, 2022, 6 (01)
  • [4] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
    Vibeke Strand
    Mark Kosinski
    Chieh-I Chen
    George Joseph
    Regina Rendas-Baum
    Neil M. H. Graham
    Hubert van Hoogstraten
    Martha Bayliss
    Chunpeng Fan
    Tom Huizinga
    Mark C. Genovese
    [J]. Arthritis Research & Therapy, 18
  • [5] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
    Strand, Vibeke
    Kosinski, Mark
    Chen, Chieh-I
    Joseph, George
    Rendas-Baum, Regina
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Bayliss, Martha
    Fan, Chunpeng
    Huizinga, Tom
    Genovese, Mark C.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [6] IMPACT OF ETANERCEPT-METHOTREXATE THERAPY ON PATIENT-REPORTED OUTCOMES IN A RANDOMIZED CONTROLLED TRIAL IN MODERATELY ACTIVE RHEUMATOID ARTHRITIS PATIENTS
    Bird, P.
    Wollenhaup, J.
    Lee, S. -H.
    Szekanecz, Z.
    Neira, O.
    Hammond, C.
    Vlahos, B.
    Szumski, A.
    Koenig, A. S.
    Kotak, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 633 - 633
  • [7] Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
    Gossec, Laure
    Baraliakos, Xenofon
    Galloway, James
    Erik, Lars
    Oke, Vilija
    Sfikakis, Petros
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Lavie, Frederic
    McInnes, Iain
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2807 - 2809
  • [8] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Vender, R.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 941 - 941
  • [9] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Chen, Linda
    Kudlacz, Elizabeth
    Wu, Joseph
    Cappelleri, Joseph C.
    Hendrikx, Thijs
    Hsu, Ming-Ann
    [J]. RMD OPEN, 2019, 5 (01):
  • [10] Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
    Kavanaugh, Arthur
    Marzo-Ortega, Helena
    Vender, Ronald
    Birt, Julie
    Adams, David
    Benichou, Olivier
    Lin, Chen-Yen
    Nash, Peter
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345